Anti-Human Galectin-9 Reference Antibody (HFB200901, RUO) (HT173036)

Name: Anti-Human Galectin-9 Reference Antibody (HFB200901, RUO)
Brand: abinScience
SKU: HT173036
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HT173036
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	HFB200901
Actividad biológica	Anti-LGALS9 (HFB200901) (10 ug/mL; 1 h) potently inhibits rLGALS9-induced vacuolization in MDCK and DLD-1 KRAS G12C mutant colon carcinoma cells [1]. HFB200901 (20 ug-10 mg; s.c.; once weekly; 8 weeks) reduces pancreatic LGALS9 expression, lowers peripheral and infiltrating Treg levels, increases pancreatic-infiltrating CD4 + T cells, and limits PanIN progression in KC mice [2].
Sistema de expresión	Mammalian cells
Objetivo	Ecalectin, LGALS9, Galectin-9, Gal-9, Tumor antigen HOM-HD-21
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	O00182
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	HFB200901
Fondo	Galectin-9 (Gal-9) is a ~39 kDa protein. Binds galactosides. Has high affinity for the Forssman pentasaccharide. Ligand for HAVCR2/TIM3. Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death. Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth. 1. Nagae, M. et al. (2008) Journal of molecular biology 375, 119-35. PMID: 18005988 2. Zhu, C. et al. (2005) Nature immunology 6, 1245-52. PMID: 16286920 3. Bi, S. et al. (2011) Proceedings of the National Academy of Sciences of the United States of America 108, 10650-5. PMID: 21670307 4. Gieseke, F. et al. (2013) European journal of immunology 43, 2741-9. PMID: 23817958 5. Mengshol, JA. et al. (2010) PloS one 5, e9504. PMID: 20209097 6. Dai, SY. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 2974-81. PMID: 16116184 7. Kojima, R. et al. (2014) PloS one 9, e86106. PMID: 24465902 9. Golden-Mason, L. et al. (2013) Journal of virology 87, 4835-45. PMID: 23408620
Referencias	1. Wiersma VR, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy. 2015;11(8):1373-1388. [HT173036] 2. Quilbe A, et al. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice. Front Immunol. 2023;14:1267279. Published 2023 Nov 30. [HT173036] 3. Pranjol M Z I, Zinovkin D A, Potapnev M P. The role of galectins in the immune microenvironment in human cancers and potential therapeutic approaches[J]. Frontiers in Immunology, 2024, 15: 1448407. [HT173036] 4. Lu B, et al. LGALS9 blockade augments vaccine-induced immune responses against prostate cancer. J Immunother Cancer. 2026;14(5):e014141. Published 2026 May 8. View More [HT173036]
Nota	For research use only. Not suitable for clinical or therapeutic use.